Plasma lipids and antidiabetic agents: a brief overview

American Diabetes Association. Position statement: Management of dyslipidemia in adults with diabetes. Diabetes Care 2001;24(suppl 1): 1-8.

Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP). JAMA 2001;285:486-96.

Haffner SM , Lehto S. , Rönnemaa T. et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction . N Engl J Med 1998;339:229-34.

American Diabetes Association. Position statement: Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care 2001;24 (suppl 1):1-10.

Herman WH , Alexander CM , Cook JR et al. Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes: Findings from the Scandinavian Simvastatin Survival Study. Diabetes Care 1999;22:1171-8.

Abhimanyu G. Dyslipoproteinemia and diabetes. Endocrinol Metab Clin 1998;27:614-25.

Caixas A. , Ordonez-Llanos J. , de Leiva A. et al. Optimization of glycemic control by insulin therapy decreases the proportion of small dense LDL particles in diabetic patients. Diabetes 1997;6:1207-13.

Edleman S. , Henry R. Insulin therapy for normalizing glycosylated hemoglobin in type II diabetes . Application, benefits, and risks. Diabetes Rev 1995;3:312-24.

Simonson DC , Kourides IA , Feinglos M. et al. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM: Results of two multicenter, randomized, placebo controlled clinical trials. Diabetes Care 1997;20:597-606.

DeFronzo RA Pharmacologic therapy for type 2 diabetes mellitus . Ann Intern Med 1999;131:281-303.

Panahloo A. Effect of insulin versus sulfonylurea therapy on cardiovascular risk factors and fibrinolysis in type II diabetics. Metabolism 1998;47:637-43.

Matsumoto K. , Miyake S. , Yano M. et al. Increase of lipoprotein (a) with troglitazone . The Lancet 1997;350:1748-9.

Billingham MS , Milles JJ , Bailey CJ et al. Lipoprotein subfraction composition in non-insulin-dependent diabetes treated by diet, sulphonylurea, and insulin . Metabolism 1989;38:850-7.

Mughal MA , Jan M. , Maheri WM et al. The effect of metformin on glycemic control, serum lipids and lipoproteins in diet alone and sulfonylurea-treated type 2 diabetic patients with sub-optimal metabolic control. J Pakistan Med Assoc 2000;50:381-6.

Robinson AC , Burke J. , Robinson S. et al. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control. Diabetes Care 1998;21:701-5.

Fanghanel G. , Sanchez-Reyes L. , Trujillo C. et al. Metformin's effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas . Diabetes Care 1996;19:1185-9.

Kiayias JA , Vlachou ED , Papadodima EL Metformin and lipoprotein(a) levels. Diabetes Care 1999;22:859.

Bell D. , Ovalle F. Metformin lowers lipoprotein(a) level. Diabetes Care 1998;21:2028.

Bell PM , Hadden DR Current therapies for diabetes-metformin. Endocrinol Metab Clin 1997;26:523-34.

Henry R. , Mudalair S. New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers. Annu Rev Med 2001;52:239-57.

Parulkar AA , Pendergrass ML , Granda-Ayala R. et al. Non hypoglycemic effects of thiazolidinediones . Ann Intern Med 2001;134:61-71.

Gavin JR III. Type 2 Diabetes: New drugs-optimal treatment strategies . Consultant 2001;4:581-9.

Winkler K. , Friedrich I. , Nauck M. et al. Pioglitazone reduces dense LDLparticles in patients with type-2 diabetes. Diabetes 2001;50(suppl 2):A147.

Tack CS , Smits P. , Demacker PN et al. Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care 1998;21:796-9.

Brunzell J. , Cohen BR , Kreider M. et al. Rosiglitazone favorably affects LDL-C and HDL-C heterogeneity in type 2 diabetes. Diabetes 2001;50(suppl 2):A141.

Nagai Y. , Abe T. , Normura G. Does pioglitazone, like troglitazone, increase lipoprotein(a) levels in diabetic patients? Diabetes Care 2001;24:408-9.

Ovalle F. , Bell D. Differing effects of thiazolidinediones on HDL subfractions and LP(a). Diabetes 2001;50(suppl 2):A461-2.

Reaven GM , Lardinois CK , Greenfield MS et al. Effect of acarbose on carbohydrate and lipid metabolism in NIDDM patients poorly controlled by sulfonylureas. Diabetes Care 1990;13(suppl 3):32-6.

Marbury T. , Huang WC , Strange P. et al. Repaglinide versus glyburide: a one-year comparison trial. Diab Res Clin Pract 1999;43:155-66.

Dunn C. , Faulds D. Nateglinide. Drugs 2000;60:607-15.

Caixas A. , Perez A. , Ordonez-Llanos J. et al. Lack of change of lipoprotein(a) levels by optimization of glycemic control with insulin therapy in NIDDM. Diabetes Care 1997;20:1459-61.

Wolffenbuttel BH , Sels JJ , Rondas-Colbers G. et al. Comparison of different insulin regimens in elderly patients with NIDDM. Diabetes Care 1996;19:1326-32.

Rivellese AA , Patti L. , Romano G. et al. Effect of insulin and sulfonylurea therapy, at the same level of blood glucose control, on low density lipoprotein subfractions in type 2 diabetic patients. J Clin Endocrinol Metab 2000;85:4188-92.

Karlander SG , Gutniak MK , Efendic S. Effects of combination therapy with glyburide and insulin on serum lipid levels in NIDDM patients with secondary sulfonylurea failure. Diabetes Care 1991;14:963-7.

Einhorn D. , Rendell M. , Egan JW et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clinical Therapeutics 2000;22:1395-409.